Overexpression of phosphorylated p27^Kip1 at threonine 187 may predict outcome in aggressive B-cell lymphomas

References

• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501–1512.
   PubMed Web of Science ®Google Scholar
• Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183:10–17.
   PubMed Web of Science ®Google Scholar
• Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227–230.
   PubMed Web of Science ®Google Scholar
• Palmqvist R, Stenling R, Oberg A, Landberg G. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. J Pathol 1999;188:18–23.
   PubMed Web of Science ®Google Scholar
• Cheville JC, Lloyd RV, Sebo TJ, et al. Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol 1998;11:324–328.
   PubMed Web of Science ®Google Scholar
• Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 1998;92:770–777.
   PubMed Web of Science ®Google Scholar
• Erlanson M, Landberg G. Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas. Leuk Lymphoma 2001;40:461–470.
   PubMed Web of Science ®Google Scholar
• Moller MB. P27 in cell cycle control and cancer. Leuk Lymphoma 2000;39:19–27.
   PubMed Web of Science ®Google Scholar
• Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999;9:661–664.
   PubMed Web of Science ®Google Scholar
• Nakayama KI, Hatakeyama S, Nakayama K. Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem Biophys Res Commun 2001;282:853–860.
   PubMed Web of Science ®Google Scholar
• Hershko D, Bornstein G, Ben-Izhak O, et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001;91:1745–1751.
   PubMedGoogle Scholar
• Masuda TA, Inoue H, Sonoda H, et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 2002;62:3819–3825.
   PubMed Web of Science ®Google Scholar
• Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002;110:633–641.
   PubMed Web of Science ®Google Scholar
• Osoegawa A, Yoshino I, Tanaka S, et al. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. J Clin Oncol 2004;22:4165–4173.
   PubMed Web of Science ®Google Scholar
• Oliveira AM, Okuno SH, Nascimento AG, Lloyd RV. Skp2 protein expression in soft tissue sarcomas. J Clin Oncol 2003;21:722–727.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Fan Y, Piva R, et al. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 2002;160:1457–1466.
   PubMedGoogle Scholar
• Lim MS, Adamson A, Lin Z, et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood 2002;100:2950–2956.
   PubMed Web of Science ®Google Scholar
• Seki R, Okamura T, Koga H, et al. Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma. Am J Hematol 2003;73:230–235.
   PubMed Web of Science ®Google Scholar
• Latres E, Chiarle R, Schulman BA, et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA 2001;98:2515–2520.
   PubMed Web of Science ®Google Scholar
• Troncone G, Martinez JC, Iaccarino A, et al. p27Kip1 is expressed in proliferating cells in its form phosphorylated on threonine 187. BMC Clin Pathol 2005;5:3.
   PubMedGoogle Scholar
• Kase S, Yoshida K, Nakayama KI, et al. Phosphorylation of p27(KIP1) in the developing retina and retinoblastoma. Int J Mol Med 2005;16:257–262.
   PubMed Web of Science ®Google Scholar
• Kase S, Yoshida K, Ohgami K, Shiratori K, Ohno S, Nakayama KI. Phosphorylation of p27(KIP1) in the mitotic cells of the corneal epithelium. Curr Eye Res 2006;31:307–312.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics: tumours of haematopoietic and lymphoid tissuesLyon: IARC Press; 2001.
   Google Scholar
• Hermans J, Krol AD, van Groningen K, et al. International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995;86:1460–1463.
   PubMed Web of Science ®Google Scholar
• Ma XM, Liu Y, Guo JW, Liu JH, Zuo LF. Relation of overexpression of S phase kinase-associated protein 2 with reduced expression of p27 and PTEN in human gastric carcinoma. World J Gastroenterol 2005;11:6716–6721.
   PubMed Web of Science ®Google Scholar
• Yang G, Ayala G, De Marzo A, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002;8:3419–3426.
   PubMed Web of Science ®Google Scholar
• Woenckhaus C, Maile S, Uffmann S, et al. Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome. Histol Histopathol 2005;20:501–508.
   PubMed Web of Science ®Google Scholar
• Li JQ, Wu F, Masaki T, et al. Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors. Int J Oncol 2004;25:87–95.
   PubMed Web of Science ®Google Scholar
• Traub F, Mengel M, Luck HJ, Kreipe HH, von Wasielewski R. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat 2006;99:185–191.
   PubMed Web of Science ®Google Scholar
• Zhu CQ, Blackhall FH, Pintilie M, et al. Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker. Clin Cancer Res 2004;10:1984–1991.
   PubMed Web of Science ®Google Scholar
• Qi CF, Xiang S, Shin MS, et al. Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas. Leuk Res 2006;30:153–163.
   PubMed Web of Science ®Google Scholar
• Saez A, Sanchez E, Sanchez-Beato M, et al. p27KIP1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome. Br J Cancer 1999;80:1427–1434.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000;95:619–626.
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L, Thieblemont C, Fend F, et al. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol 1998;153:175–182.
   PubMed Web of Science ®Google Scholar
• Sanchez-Beato M, Saez AI, Martinez-Montero JC, et al. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol 1997;151:151–160.
   PubMed Web of Science ®Google Scholar
• Alkarain A, Slingerland J. Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer. Breast Cancer Res 2004;6:13–21.
   PubMed Web of Science ®Google Scholar
• Barnes A, Pinder SE, Bell JA, et al. Expression of p27kip1 in breast cancer and its prognostic significance. J Pathol 2003;201:451–459.
   PubMed Web of Science ®Google Scholar
• Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C. p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res Treat 2001;67:15–22.
   PubMed Web of Science ®Google Scholar
• Nicolaides C, Fountzilas G, Zoumbos N, et al. Diffuse large cell lymphomas: identification of prognostic factors and validation of the international non-Hodgkin's lymphoma prognostic index. A Hellenic Cooperative Oncology Group Study. Oncology 1998;55:405–415.
   PubMed Web of Science ®Google Scholar
• Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994;83:1460–1466.
   PubMed Web of Science ®Google Scholar
• Sanchez E, Chacon I, Plaza MM, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998;16:1931–1939.
   PubMed Web of Science ®Google Scholar
• Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol 2009;84:338–343.
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Anderson H, Dictor M, Kvaloy S, AkermanM, Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. Ann Hematol 2004;83:414–419.
   PubMed Web of Science ®Google Scholar
• Hasselblom S, Ridell B, Sigurdardottir M, Hansson U, Nilsson-Ehle H, Andersson PO. Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Leuk Lymphoma 2008;49:1501–1509.
   PubMed Web of Science ®Google Scholar